Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Evotec SE EVO
$10.37
-$0.12 (-1.14%)
На 18:05, 12 мая 2023
+15.72%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
3305472625.00000000
-
week52high
15.04
-
week52low
7.80
-
Revenue
618034000
-
P/E TTM
-20
-
Beta
1.07442700
-
EPS
-0.58000000
-
Last Dividend
14.49589900
-
Next Earnings Date
29 мар 2023 г. в 01:00
Описание компании
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Overweight | 10 авг 2022 г. |
| Cowen & Co. | Outperform | 29 ноя 2021 г. | |
| Deutsche Bank | Hold | Buy | 16 ноя 2022 г. |
| Stifel | Hold | Buy | 15 авг 2016 г. |
| HC Wainwright & Co. | Buy | 09 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Evotec SE (EVOTF) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 15:10
Evotec SE (OTCPK:EVOTF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets Christian Ehmann - Warburg Research James Quigley - Morgan Stanley Derik de Bruin - Bank of America Peter Welford - Jefferies Joe Hedden - Rx Securities Steven Mah - Cowen Falko Friedrichs - Deutsche Bank Victoria English - Evernow Publishing Limited Werner Lanthaler Good morning, good afternoon. Welcome from Evotec.
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
Accesswire
03 ноя 2022 г. в 07:15
HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.
Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
13 авг 2022 г. в 07:29
Evotec SE (OTCPK:EVOTF) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets James Quigley - Morgan Stanley Christian Ehmann - Warburg Research Steven Mah - Cowen Derik de Bruin - Bank of America Falko Friedrichs - Deutsche Bank Joseph Hedden - Rx Securities Operator Good day, ladies and gentlemen. And welcome to the Evotec SE Half Year Report 2022 Conference Call.
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
Accesswire
04 авг 2022 г. в 05:30
HAMBURG, GERMANY / ACCESSWIRE / August 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Zacks Investment Research
15 июн 2022 г. в 12:20
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.